Literature DB >> 2158277

Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa.

B L Masecar1, R A Celesk, N J Robillard.   

Abstract

Decreasing susceptibility to ciprofloxacin was investigated in sequential clinical isolates of Pseudomonas aeruginosa from a patient on ciprofloxacin therapy. All isolates were verified as the same strain by DNA probe. MICs of all quinolones tested were 16- to 32-fold higher for the posttherapy isolates; nonquinolone MICs were unchanged. The isolates were compared by analyses of outer membrane proteins and lipopolysaccharide composition, antimicrobial susceptibilities, measurement of accumulation of ciprofloxacin, and inhibition of DNA gyrase activity by ciprofloxacin and nalidixic acid. No significant changes in outer membrane proteins or ciprofloxacin accumulation were observed; however, both posttherapy isolates lost the long chain O-polysaccharide component of lipopolysaccharide. Preparations of DNA gyrase from the quinolone-resistant posttherapy isolates were 16- to 32-fold less sensitive to inhibition of supercoiling by ciprofloxacin and nalidixic acid than was gyrase from the pretherapy isolate. Inhibition studies on combinations of heterologous gyrase subunits showed that decreased inhibition was conferred by the resistant gyrase A subunits. Thus, acquired resistance to ciprofloxacin in this strain involved an alteration in the A subunit of DNA gyrase and was associated with changes in lipopolysaccharide.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158277      PMCID: PMC171574          DOI: 10.1128/AAC.34.2.281

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.

Authors:  M A Gonzalez; A H Moranchel; S Duran; A Pichardo; J L Magana; B Painter; A Forrest; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

2.  Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria.

Authors:  S Mehtar; Y Drabu; P Blakemore
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

3.  Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli.

Authors:  K Hirai; H Aoyama; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

4.  Correlation between lipopolysaccharide structure and permeability resistance in beta-lactam-resistant Pseudomonas aeruginosa.

Authors:  A J Godfrey; L Hatlelid; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

5.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Resistance of Pseudomonas aeruginosa to new beta-lactamase-resistant beta-lactams.

Authors:  A J Godfrey; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

7.  Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.

Authors:  L J Eron; L Harvey; D L Hixon; D M Poretz
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

8.  DNA gyrase (Topoisomerase II) from Pseudomonas aeruginosa.

Authors:  R V Miller; T R Scurlock
Journal:  Biochem Biophys Res Commun       Date:  1983-01-27       Impact factor: 3.575

9.  Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu; M F Parry; W Mandell
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321

10.  Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

Authors:  F Follath; M Bindschedler; M Wenk; R Frei; H Stalder; H Reber
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

View more
  22 in total

1.  A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa.

Authors:  L J Piddock; M C Hall; F Bellido; M Bains; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.

Authors:  R R Muder; C Brennen; A M Goetz; M M Wagener; J D Rihs
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA.

Authors:  B L Masecar; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

4.  Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

Authors:  J M Diver; T Schollaardt; H R Rabin; C Thorson; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

5.  Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.

Authors:  N Nakanishi; S Yoshida; H Wakebe; M Inoue; T Yamaguchi; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

6.  Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin.

Authors:  Catherine Llanes; Thilo Köhler; Isabelle Patry; Barbara Dehecq; Christian van Delden; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

Review 7.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones.

Authors:  S Bazile; N Moreau; D Bouzard; M Essiz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

9.  Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.

Authors:  C R Marchbanks; J R McKiel; D H Gilbert; N J Robillard; B Painter; S H Zinner; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

10.  Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis.

Authors:  N Nakanishi; S Yoshida; H Wakebe; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.